Maxion Therapeutics (Series A)
Funding Details
- Awarder
- Inbox
- Date Award
- March 17, 2025
- Vertical
- Biotech
- Funding URL
- View Funding Page
- Funding Amount:
- $58,000,000
Company Info
- Founding Year
- 2020
- Traction
- Secured £58M in an oversubscribed Series A round and received a £2 million grant from Innovate UK to advance its ion channel antibody development.
- Founders
- John McCafferty, Aneesh Karatt-Vellatt
- Company Description
- Maxion Therapeutics is a biotech company developing antibody-based KnotBody® drugs for ion channel and G protein-coupled receptor (GPCR) driven diseases, utilizing a proprietary platform that combines antibodies with cysteine-rich miniproteins to create potent and selective treatments.
- Market
- Biologic drug development for ion channel and GPCR-driven diseases
- Location
- Cambridge, UK
- Coinvestors
- General Catalyst, British Patient Capital, Solasta Ventures, Eli Lilly and Company, LifeArc Ventures, Monograph Capital, BGF